Based on this trial, the FDA granted accelerated approval to pembrolizumab for patients with recurrent locally advanced or metastatic GC or GEJ adenocarcinoma with PD‐L1 CPS ≥ 1. This evidence concerns the gene CD274 and gastric cancer.